5244042025-10-012025-12-315244042025-12-315244042025-04-012025-12-315244042025-10-012025-12-31in-capmkt:OtherExpenses1Member5244042025-04-012025-12-31in-capmkt:OtherExpenses1Member5244042025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15244042025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15244042025-10-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss15244042025-04-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss15244042025-10-012025-12-31AuditorDomain15244042025-12-31Statement15244042025-10-012025-12-31Statement15244042025-12-31StatementDynamic1I1Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares524404MARKSANSNOTLISTEDINE750C01026MARKSANS PHARMA LIMITEDMain BoardEquity2025-04-012026-03-312026-02-052026-01-09INRMillionsQuarterlyThird quarterSingle segmentPharmaceutical Formulation2026-02-0512:25:002026-02-0513:15:00Declaration of unmodified opiniontrue1falseThe Company has no outstanding loans and debt securities.2025-10-012025-12-31UnauditedStandalone3397290000158580000355587000015100300001601900006176000032704000035700008830000058382000027347100008211600000821160000208390000365000021204000006091200000000609120000934000061846000045316000011.341.34001.341.34NOTES TO STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025. <BR> <BR> 1. The standalone unaudited financial results for the quarter and nine months ended 31 December 2025 <BR> were reviewed by the Audit Committee and approved by the Board of Directors at their respective <BR> meeting held on 05 February 2026. The Statutory Auditors of the Company have carried out <BR> limited review on the above results in terms of Regulation 33 of the SEBI (Listing Obligation and <BR> Disclosure Requirements) Regulations, 2015 ('the Regulation'), as amended and expressed an <BR> unmodified conclusion. <BR> <BR> 2. The standalone unaudited financial results of the Company have been prepared in accordance <BR> with the recognition and measurement principles laid down in the Indian Accounting Standard 34 <BR> ‘Interim Financial Reporting’, prescribed under Section 133 of the Companies Act, 2013 read with <BR> relevant rules issued thereunder and other recognised accounting principles generally accepted in <BR> India and in terms of the Regulation. <BR> <BR> 3. The Company operates in one reportable business segment namely 'Pharmaceuticals' as per Ind <BR> AS 108 on 'Operating Segments'. <BR> <BR> 4. Other income (net) includes the following net foreign exchange differences including forward contracts: <BR> <BR> Description Quarter ended Nine Months ended Year Ended <BR> 31-Dec-25 30-Sep-25 31-Dec-24 31-Dec-25 31-Dec-24 31-Mar-25 <BR> <BR> Net gain / (loss) 117.75 175.10 265.38 255.12 169.00 194.80 <BR> <BR> 5. During nine months ended 31 December 2025, the Board of Directors and Shareholders of the <BR> Company have approved the Marksans Employees Stock Option Scheme 2024 ("Scheme") for the <BR> employees of the Company and its subsidiary companies comprising of equity shares of the <BR> Company, not exceeding 2,300,000 equity share of face value of Re 1/- each. Under the said <BR> Scheme, the Company has granted 400,000 equity stock options of face value of Re 1/- each on 24 <BR> September 2025 to the eligible employees of the Company and its Subsidiary Companies.2025-04-012025-12-31UnauditedStandalone979904000076057000010559610000442944000059803000071200008906300009740000254750000169806000078877700002671840000026718400005618200002227000058409000002087750000000020877500007830000209558000045316000014.614.61004.614.61Other Expenses583820000Other Expenses1698060000Remeasurements of the net defined benefit liabilities/assets1248000012480000Remeasurements of the net defined benefit liabilities/assets104700001047000031400002640000Remeasurements of the net defined benefit liabilities/assets00Remeasurements of the net defined benefit liabilities/assets000093400007830000UnauditedtrueMSKA & Associates LLPtrue2027-07-31Preferential Issues2023-01-1837240000002025-12-31falsefalseNo deviation / variationSatisfactoryfalseHarshavardhan PanigrahiCompany Secretary and Compliance OfficerMumbai2026-02-05Expansion ProgrammeNo3724000000037240000000